查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000756

新冠病毒检测市场：2026年至2032年全球市场预测（依检测类型、检体类型、产品类型、通路和最终用户划分）

COVID-19 Testing Market by Test Type, Sample Type, Product Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，COVID-19 检测市场价值将达到 467.3 亿美元，到 2026 年将成长至 512.5 亿美元，到 2032 年将达到 952 亿美元，复合年增长率为 10.69%。

主要市场统计数据
基准年 2025 467.3亿美元
预计年份：2026年 512.5亿美元
预测年份 2032 952亿美元
复合年增长率 (%) 10.69%

对不断变化的 COVID-19 检测格局进行清晰的概述，阐明诊断方案、操作权衡以及相关人员的策略决策因素。

受科学进步、公共卫生优先事项转变以及全球供应链波动的影响，新冠病毒检测格局持续快速变化。本执行摘要总结了最重要的趋势，旨在为临床检查室、製造商、政策制定者和采购团队的决策提供支援。它探讨了诊断方法的技术进步以及监管调整、供应韧性和分散式检查模式普及等实际操作问题，揭示了这些因素如何影响临床环境和社区中检测的开展和评估方式。

快速的技术创新、分散的护理路径和监管柔软性如何从根本上改变诊断服务模式和策略重点。

创新、去中心化和监管柔软性改变了我们的诊断方式，既带来了颠覆性变革，也拓展了诊断的可能性。科技进步丰富了临床医生和消费者可用的工具，尤其是在高灵敏度、倍增式分子检测和易于操作的快速抗原检测等领域。这些创新催生了一种新的操作模式。检测不再是中心检查室的专属领域；就地检验和居家检测在早期发现、治疗方法选择和社区监测方面发挥着越来越重要的作用。

本检验了不断变化的贸易措施如何重塑整个诊断测试生态系统的筹资策略、製造选择和采购惯例。

美国关税调整和贸易政策措施对新冠病毒检测价值链产生了重大影响，进而影响诊断材料的相对成本、供应和分销。关键零件进口关税的提高推高了检测套组生产商和组装的投入成本，可能挤压利润空间，迫使他们将成本转嫁给买家。除了对单价的影响外，关税还改变了筹资策略策略，促使供应商实现地理多元化，并重新重视本地生产能力，以保护关键诊断设备免受国际贸易波动的影响。

清楚了解每个细分市场的测试方法、检体选择和最终用户管道如何相互交织，从而确定诊断的效用和操作可行性。

对市场区隔的精准理解能够揭示哪些领域的投资和营运改善将产生最大的影响。从检测类型来看，市场涵盖抗体检测、抗原检测和即时PCR检测，其中即时PCR又可根据技术进步进一步细分，例如数位PCR、多重PCR和定量PCR。每种检测方法都有不同的性能和操作特性。抗体检测可用于血清阳性率和回顾性暴露分析，抗原检测可实现快速照护现场筛检（POC​​），而各种PCR检测则可用于诊断确认、病毒量评估和多病原体检测。

此区域分析表明，基础设施、监管和製造业实力如何影响主要全球路线的检查准入和营运策略。

区域趋势正在影响新冠病毒检测的取得、部署和运作方式，一些关键区域的趋势尤其明显。在美洲，诊断网络优先考虑规模和容量，整合的检测服务和充足的检测能力支持分子和抗原诊断平台的广泛部署。法规环境有助于快速紧急核准和切实可行的报销方案，从而加速创新检测方式的采用，同时，强有力的品质保证对于维持临床可靠性至关重要。

深入了解引领诊断技术创新和供应可靠性的领导企业的竞争定位、伙伴关係关係结构和产能投资。

新冠病毒检测领域的竞争趋势呈现出快速产品创新、策略伙伴关係和围绕核心能力进行整合的趋势。主要企业正投资于兼具卓越分析效能和易用性、强大的供应链网路以及与医疗系统整合的数据报告功能的诊断平台。试剂供应商、仪器製造商和检查室网路之间的合作正在加快新检测产品的上市速度并提高分销效率，而与物流和低温运输供应商的伙伴关係则正在解决「最后一公里」配送难题。

诊断设备製造商和服务供应商可采取的策略重点，以建立具有韧性的供应链、模组化产品和以客户为中心的交付模式。

产业领导企业应采取多元化策略，重点关注具有韧性的供应链、模组化产品设计和数据驱动的服务交付。优先考虑关键原材料来源多元化，并制定紧急时应对计画，包括合格的替代供应商和本地生产能力，以降低贸易中断带来的风险。将供应链压力测试纳入日常规划週期，全面了解上游供应商网络，以便在瓶颈影响交付之前预测其出现。

透过结合专家访谈、文件分析和情境调查方法，我们得出可靠的诊断见解，这些见解可直接影响决策。

本研究整合了一手和二手资料，旨在得出更注重实际应用而非推测性的结论。一手资料包括与研究主任、采购负责人和临床营运经理的系统性讨论，以及与供应链经理和产品开发主管的专案访谈。基于这些讨论，我们对压力环境下的营运重点、产品绩效权衡和采购行为进行了定性评估。

总结整合重点在于永续的诊断策略、弹性运作以及数位化和商业性创新整合，以实现长期价值。

新冠病毒检测体系已从临时性的紧急应变阶段发展到系统化的成熟阶段，其特点是技术先进、供应链管理策略完善以及监管标准不断完善。目前的诊断策略需要采取平衡的方法，包括选择具有临床意义的检测方法、制定稳健的采购和生产计划，以及建立贯穿整个生命週期的营运绩效监控机制。决策者必须持续评估平台能力与实际营运状况的匹配度，以确保投资能够支援永续的服务交付，而非仅仅满足短期需求激增。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 新冠病毒检测市场（依检测类型划分）

  • 分子检测
    • 单一标靶RT-PCR
    • 多重RT-PCR
    • 等温扩增试验
  • 抗原检测
    • 检查室抗原检测
    • 家用抗原检测
  • 血清学检测

第九章 新冠病毒检测市场（依检体类型划分）

  • 上呼吸道检体
    • 鼻咽拭子
    • 口腔和咽拭子
    • 前鼻腔拭子
  • 下呼吸道检体
    • 痰
    • 支气管肺泡灌洗液
    • 气管抽吸物
  • 唾液检体
  • 血液和血浆检体

第十章：新冠病毒检测市场：依产品类型划分

  • 检测套组和试剂
    • 分子检测套组
    • 抗原检测套组
    • 血清检测套组
    • 控制和校准器
    • 样品製备试剂
  • 服务
    • 检查服务
    • 外包测试服务
    • 数据分析和报告服务

第十一章：新冠病毒侦测市场：依通路划分

  • 直销
  • 零售通路
  • 线上管道
    • 厂商官方网路商店
    • 第三方电子商务平台

第十二章：新冠病毒检测市场：依最终用户划分

  • 医院和诊所
    • 急诊医院
    • 专科医院
    • 门诊部
  • 诊断检测实验室
    • 独立检测实验室
    • 医院检查室
  • 诊所
  • 学术研究机构

第十三章：新冠病毒侦测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：新冠病毒检测市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：新冠病毒检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国新冠病毒检测市场

第十七章：中国的COVID-19检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AccuBioTech Co. Ltd.
  • ADT Biotech
  • AIVD Biotech Inc.
  • Altona Diagnostics GmbH
  • AMEDA Labordiagnostik GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cepheid Inc.
  • Coris BioConcept SPRL
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • GenBody America, LLC
  • Genuine Biosystem Pvt. Ltd.
  • Hologic Inc.
  • LAB-CARE DIAGNOSTICS（INDIA）PVT. LTD.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • PerkinElmer Inc.
  • Quest Diagnostics Inc.
  • Quidel Corporation
  • SD Biosensor, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-02026C4C986E

The COVID-19 Testing Market was valued at USD 46.73 billion in 2025 and is projected to grow to USD 51.25 billion in 2026, with a CAGR of 10.69%, reaching USD 95.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 46.73 billion
Estimated Year [2026] USD 51.25 billion
Forecast Year [2032] USD 95.20 billion
CAGR (%) 10.69%

An incisive overview of the evolving COVID-19 testing environment that clarifies diagnostic choices, operational trade-offs, and strategic decision levers for stakeholders

The COVID-19 testing environment continues to evolve at pace, shaped by scientific advances, shifting public health priorities, and changes across global supply chains. This executive summary synthesizes the most salient developments that inform decision-making for clinical laboratories, manufacturers, policy makers, and procurement teams. It frames the technical progress in diagnostic modalities alongside operational realities-regulatory adaptation, supply resilience, and the diffusion of decentralized testing models-that together define how testing is delivered and valued in clinical and community settings.

Across settings, stakeholders must weigh the clinical performance characteristics of assays against practical considerations such as turnaround time, ease of use, and sample type compatibility. This balance drives adoption patterns and determines which testing pathways are best suited to specific use cases, from hospital triage to at-home surveillance. The introduction of more refined molecular techniques and the normalization of antigen-based rapid testing have both complemented and contested the central role of traditional laboratory-based PCR, prompting organizations to reassess workflows, staffing models, and investment priorities.

Finally, the introduction outlines how this report focuses on actionable intelligence. It prioritizes insights that help leaders navigate procurement complexity, optimize testing portfolios, and align diagnostic strategies with broader public health and commercial objectives. The content that follows emphasizes practical implications rather than raw estimates, offering a foundation for resilient, evidence-based decision-making as the diagnostic landscape continues to mature.

How rapid technological innovation, decentralized care pathways, and regulatory agility are fundamentally transforming diagnostic delivery models and strategic priorities

Innovation, decentralization, and regulatory flexibility have collectively reshaped the diagnostic landscape in ways that are both disruptive and enabling. Technological advances have expanded the toolkit available to clinicians and consumers, notably through more sensitive and multiplexed molecular assays as well as rapid antigen formats optimized for ease of administration. These innovations have created new operational paradigms: testing is no longer the exclusive domain of centralized laboratories, and point-of-care or at-home testing increasingly contributes to early detection, therapeutics triage, and community surveillance.

Concurrently, policy shifts have encouraged faster regulatory pathways and adaptive reimbursement structures, which accelerates market entry while raising the bar for post-market performance monitoring. The net effect is a more dynamic ecosystem in which manufacturers, service providers, and health systems must iterate rapidly to maintain relevance. Supply chain sophistication has become a strategic differentiator; organizations that invest in diversified sourcing, flexible manufacturing, and vertically integrated reagent pipelines are better positioned to respond to sudden demand surges or material bottlenecks.

As the landscape transforms, the winners will be those that align product innovation with user-centered deployment models, strengthen partnerships across the diagnostic value chain, and embed real-world performance feedback into product development. These shifts require coordinated planning across R&D, regulatory, procurement, and commercial teams to capture value from emerging opportunities while managing operational risk.

Examining how evolving trade measures are reshaping sourcing strategies, manufacturing choices, and procurement practices across the diagnostic testing ecosystem

Tariff changes and trade policy measures in the United States have material implications for the COVID-19 testing value chain, influencing the relative cost, availability, and distribution of diagnostic supplies. Increased import duties on critical components can raise input costs for assay manufacturers and test kit assemblers, which in turn places pressure on margins or necessitates cost pass-throughs for purchasers. Beyond unit cost effects, tariffs alter procurement calculus by incentivizing regional diversification of suppliers and renewed emphasis on local manufacturing capabilities to shield essential diagnostics from international trade volatility.

The cumulative impact extends to supply chain timing and inventory strategies. Organizations respond to tariff-driven uncertainty by expanding safety stocks of high-use reagents and consumables, negotiating longer-term contracts with tier-one suppliers, and qualifying alternative component sources. These responses can mitigate immediate availability risks but also increase working capital requirements and warehousing overhead. Concurrently, raw material and component manufacturers may accelerate investments to move certain stages of production onshore or to tariff-exempt jurisdictions, reshaping supplier landscapes and partnership structures.

Policy reaction from procurement authorities and health systems often includes a greater willingness to support domestic production through targeted procurement preference, advance purchase commitments, or incentives for facility upgrades. For decision-makers, the strategic focus should be on building flexible sourcing frameworks, validating multi-sourced supply streams, and engaging in scenario-based planning that anticipates both trade disruptions and shifting regulatory conditions. Such preparedness reduces operational fragility and preserves continuity of testing services under varied trade regimes.

Segment-driven clarity on how test modalities, specimen choices, and end-user channels intersect to determine diagnostic utility and operational feasibility

A nuanced understanding of segmentation informs where investments and operational enhancements deliver the greatest impact. When viewed through the lens of test type, the market spans antibody testing, antigen testing, and Real Time PCR testing, with Real Time PCR further differentiated by advances such as Digital PCR, Multiplex PCR, and Quantitative PCR. Each modality carries distinct performance and operational profiles: antibody assays support seroprevalence and retrospective exposure analyses, antigen tests enable rapid point-of-care screening, and the various forms of PCR serve diagnostic confirmation, viral load assessment, and multiplexed pathogen detection.

Sample matrix selection further refines deployment decisions, as blood-based assays are typically leveraged for serological insights while nasopharyngeal swabs, oropharyngeal swabs, and saliva each present trade-offs between sensitivity, patient comfort, and collection logistics. The choice of sample type influences clinical workflows, specimen transport requirements, and biosafety protocols, and therefore merits careful alignment with intended use cases.

End-user channels complete the segmentation picture: diagnostic laboratories focus on high-throughput, highly controlled environments; home use reflects the rise of consumer-directed testing and self-collection models; hospitals and clinics prioritize rapid diagnostic turnarounds that inform immediate care decisions; and research institutes drive assay validation, variant surveillance, and methodological innovation. Understanding how test types map to sample types and end users clarifies where diagnostic utility, reimbursement potential, and operational feasibility converge, enabling stakeholders to design offerings that match clinical demands and user capabilities.

A regionally differentiated analysis showing how infrastructure, regulation, and manufacturing strengths shape testing access and operational strategies across global corridors

Regional dynamics shape access, adoption, and operational approaches to COVID-19 testing, with distinct trends emerging across major geographies. In the Americas, diagnostic networks emphasize scale and throughput, with consolidated laboratory services and substantial testing capacity that supports wide deployment of both molecular and antigen platforms. The regulatory environment tends to favor rapid emergency authorizations and pragmatic reimbursement arrangements, which accelerates adoption of innovative testing formats while also necessitating robust quality assurance to maintain clinical reliability.

In Europe, Middle East & Africa, diverse health system maturity levels and procurement capacities lead to a heterogeneous landscape. High-income European markets combine stringent regulatory oversight with strong laboratory infrastructure, enabling advanced molecular applications and centralized sequencing for variant tracking. Conversely, many middle- and low-income countries within the broader region prioritize cost-effective antigen testing and pooled testing strategies to expand coverage. Cross-border collaboration and multilateral procurement mechanisms play an important role in smoothing supply imbalances and accelerating access in resource-constrained settings.

Asia-Pacific presents a spectrum of rapid innovation and manufacturing strength. Several economies in the region possess significant production capacity for reagents, kits, and instrumentation, which supports export-oriented supply chains as well as domestic deployment. Policymakers in many jurisdictions have promoted early adoption of decentralized testing models and invested in digital integration to streamline reporting and public health responses. Taken together, regional nuances demand tailored commercialization, regulatory, and supply strategies that reflect local infrastructure, payer models, and public health priorities.

Insights into competitive positioning, partnership architectures, and capability investments that define leaders in diagnostic innovation and supply reliability

Competitive dynamics within the COVID-19 testing sector are characterized by rapid product innovation, strategic partnerships, and a wave of consolidation around core capabilities. Leading organizations are investing in diagnostics platforms that combine strong analytical performance with ease of use, robust supply networks, and integrated data reporting to health systems. Collaboration between reagent suppliers, instrument manufacturers, and laboratory networks accelerates time-to-market for new assays and enhances distribution efficiency, while partnerships with logistics and cold-chain providers address last-mile delivery challenges.

Investment in quality systems and post-market surveillance has become a reputational and regulatory imperative, prompting companies to strengthen clinical validation programs and real-world performance monitoring. Firms that demonstrate consistent operational reliability and transparent data on test performance are more successful at securing procurement contracts with healthcare systems and public agencies. Additionally, firms focused on modularity-enabling assay upgrades, multiplexing capabilities, and digital connectivity-are better positioned to adapt to variant emergence and evolving clinical needs.

For industry participants, the strategic priority is to align R&D, supply chain resilience, and commercial execution. Building scalable manufacturing footprints, diversifying supplier bases, and offering flexible commercial models such as subscription testing services or reagent-as-a-service agreements help firms capture long-term relationships with customers and mitigate cyclical demand fluctuations.

Actionable strategic priorities for diagnostic manufacturers and service providers to build resilient supply chains, modular products, and customer-centric delivery models

Industry leaders should adopt a multi-dimensional strategy that emphasizes resilient supply chains, modular product design, and data-enabled service offerings. Prioritize diversification of critical input sources and develop contingency plans that include qualified alternative suppliers and localized production capacity to reduce exposure to trade disruptions. Integrate supply chain stress testing into routine planning cycles and maintain visibility across the upstream supplier network to anticipate bottlenecks before they impact delivery.

In parallel, invest in product architectures that are adaptable-design assays and platforms that can be updated for new targets, support multiplexing, and interface with digital reporting systems. This adaptability lowers the cost of future-proofing and increases the lifespan of deployed instruments. Embrace partnerships with clinical laboratories and health systems to co-develop workflows that optimize test placement between centralized and decentralized settings, ensuring the right test is delivered in the right context.

Finally, enhance commercialization by aligning pricing and contracting models with customer needs, offering flexible purchasing terms, and bundling analytic services. Strengthen post-market surveillance and real-world evidence programs to build trust and demonstrate sustained performance. By combining operational resilience with product agility and customer-centric commercial approaches, industry leaders can capture growth opportunities while safeguarding service continuity.

Methodological approach combining expert consultation, documentary analysis, and scenario testing to produce robust, decision-oriented diagnostic insights

This research synthesizes primary and secondary intelligence to produce insights that emphasize practical implications over speculative projections. Primary inputs included structured consultations with laboratory directors, procurement officers, and clinical affairs leaders, together with targeted interviews of supply chain managers and product development executives. These discussions informed qualitative assessments of operational priorities, product performance trade-offs, and procurement behaviors under stress conditions.

Secondary analysis drew upon peer-reviewed literature, regulatory guidance documents, and public health agency releases to validate technical performance claims and to contextualize policy dynamics. Cross-referencing multiple sources enabled triangulation of key themes, particularly in areas such as assay sensitivity trade-offs, sample type performance nuances, and policy responses to supply challenges. Data interpretation prioritized reproducibility and transparency, with methodological notes and criteria for source inclusion documented in the full report annex.

The study used scenario-based modeling to stress test supply chain and procurement responses to policy disruptions, with sensitivity analyses that explore plausible alternative outcomes. Wherever possible, the methodology emphasized traceable evidence and expert corroboration to ensure findings are robust and practically relevant for decision-makers seeking to operationalize diagnostic strategies.

Concluding synthesis emphasizing sustainable diagnostic strategies, resilient operations, and the integration of digital and commercial innovations for long-term value

The COVID-19 testing ecosystem has moved from emergency improvisation to structured maturation, defined by technological refinement, strategic supply chain management, and evolving regulatory norms. Diagnostic strategies now require a balanced approach that matches assay selection to clinical purpose, incorporates resilient sourcing and manufacturing planning, and embeds real-world performance monitoring into lifecycle management. Decision-makers must continually reassess the alignment between platform capabilities and operational realities, ensuring that investments support sustainable service delivery rather than short-term demand spikes.

Looking ahead, the capacity to integrate diagnostics with digital reporting systems and to offer flexible commercial arrangements will distinguish market leaders. Likewise, organizations that invest in adaptable assay designs and diversified manufacturing footprints will be better positioned to manage policy changes and supply interruptions. Ultimately, successful navigation of the next phase of the testing landscape will depend on coordinated planning across clinical, commercial, and operational functions, underpinned by evidence-based approaches and pragmatic risk management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Testing Market, by Test Type

  • 8.1. Molecular Tests
    • 8.1.1. Single Target RT-PCR
    • 8.1.2. Multiplex RT-PCR
    • 8.1.3. Isothermal Amplification Tests
  • 8.2. Antigen Tests
    • 8.2.1. Laboratory Antigen Tests
    • 8.2.2. At Home Antigen Tests
  • 8.3. Serology Tests

9. COVID-19 Testing Market, by Sample Type

  • 9.1. Upper Respiratory Samples
    • 9.1.1. Nasopharyngeal Swab
    • 9.1.2. Oropharyngeal Swab
    • 9.1.3. Anterior Nasal Swab
  • 9.2. Lower Respiratory Samples
    • 9.2.1. Sputum
    • 9.2.2. Bronchoalveolar Lavage
    • 9.2.3. Tracheal Aspirate
  • 9.3. Saliva Samples
  • 9.4. Blood And Plasma Samples

10. COVID-19 Testing Market, by Product Type

  • 10.1. Test Kits And Reagents
    • 10.1.1. Molecular Test Kits
    • 10.1.2. Antigen Test Kits
    • 10.1.3. Serology Test Kits
    • 10.1.4. Controls And Calibrators
    • 10.1.5. Sample Preparation Reagents
  • 10.2. Services
    • 10.2.1. Laboratory Testing Services
    • 10.2.2. Outsourced Testing Services
    • 10.2.3. Data Analytics And Reporting Services

11. COVID-19 Testing Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Retail Channels
  • 11.3. Online Channels
    • 11.3.1. Manufacturer Online Stores
    • 11.3.2. Third Party E Commerce Platforms

12. COVID-19 Testing Market, by End User

  • 12.1. Hospitals And Clinics
    • 12.1.1. Acute Care Hospitals
    • 12.1.2. Specialty Hospitals
    • 12.1.3. Outpatient Clinics
  • 12.2. Diagnostic Laboratories
    • 12.2.1. Independent Reference Laboratories
    • 12.2.2. Hospital Affiliated Laboratories
  • 12.3. Physician Offices
  • 12.4. Academic And Research Institutes

13. COVID-19 Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. COVID-19 Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. COVID-19 Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States COVID-19 Testing Market

17. China COVID-19 Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AccuBioTech Co. Ltd.
  • 18.7. ADT Biotech
  • 18.8. AIVD Biotech Inc.
  • 18.9. Altona Diagnostics GmbH
  • 18.10. AMEDA Labordiagnostik GmbH
  • 18.11. Becton, Dickinson and Company
  • 18.12. Bio-Rad Laboratories, Inc.
  • 18.13. bioMerieux SA
  • 18.14. Cepheid Inc.
  • 18.15. Coris BioConcept SPRL
  • 18.16. Danaher Corporation
  • 18.17. F. Hoffmann-La Roche AG
  • 18.18. GenBody America, LLC
  • 18.19. Genuine Biosystem Pvt. Ltd.
  • 18.20. Hologic Inc.
  • 18.21. LAB-CARE DIAGNOSTICS (INDIA) PVT. LTD.
  • 18.22. Laboratory Corporation of America Holdings
  • 18.23. Luminex Corporation
  • 18.24. PerkinElmer Inc.
  • 18.25. Quest Diagnostics Inc.
  • 18.26. Quidel Corporation
  • 18.27. SD Biosensor, Inc.
  • 18.28. Siemens Healthineers AG
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY SINGLE TARGET RT-PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY SINGLE TARGET RT-PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 TESTING MARKET SIZE, BY SINGLE TARGET RT-PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX RT-PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX RT-PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX RT-PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 TESTING MARKET SIZE, BY AT HOME ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 TESTING MARKET SIZE, BY AT HOME ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 TESTING MARKET SIZE, BY AT HOME ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTERIOR NASAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTERIOR NASAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTERIOR NASAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 TESTING MARKET SIZE, BY TRACHEAL ASPIRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 TESTING MARKET SIZE, BY TRACHEAL ASPIRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 TESTING MARKET SIZE, BY TRACHEAL ASPIRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD AND PLASMA SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD AND PLASMA SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD AND PLASMA SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 TESTING MARKET SIZE, BY MOLECULAR TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COVID-19 TESTING MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COVID-19 TESTING MARKET SIZE, BY CONTROLS AND CALIBRATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COVID-19 TESTING MARKET SIZE, BY CONTROLS AND CALIBRATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COVID-19 TESTING MARKET SIZE, BY CONTROLS AND CALIBRATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE PREPARATION REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE PREPARATION REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE PREPARATION REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COVID-19 TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COVID-19 TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COVID-19 TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COVID-19 TESTING MARKET SIZE, BY LABORATORY TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTSOURCED TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTSOURCED TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTSOURCED TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COVID-19 TESTING MARKET SIZE, BY DATA ANALYTICS AND REPORTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COVID-19 TESTING MARKET SIZE, BY DATA ANALYTICS AND REPORTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COVID-19 TESTING MARKET SIZE, BY DATA ANALYTICS AND REPORTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COVID-19 TESTING MARKET SIZE, BY RETAIL CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COVID-19 TESTING MARKET SIZE, BY RETAIL CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COVID-19 TESTING MARKET SIZE, BY RETAIL CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COVID-19 TESTING MARKET SIZE, BY MANUFACTURER ONLINE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COVID-19 TESTING MARKET SIZE, BY MANUFACTURER ONLINE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COVID-19 TESTING MARKET SIZE, BY MANUFACTURER ONLINE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COVID-19 TESTING MARKET SIZE, BY THIRD PARTY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COVID-19 TESTING MARKET SIZE, BY THIRD PARTY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COVID-19 TESTING MARKET SIZE, BY THIRD PARTY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACUTE CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACUTE CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACUTE CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COVID-19 TESTING MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COVID-19 TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COVID-19 TESTING MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COVID-19 TESTING MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL COVID-19 TESTING MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITAL AFFILIATED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITAL AFFILIATED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITAL AFFILIATED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL COVID-19 TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL COVID-19 TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL COVID-19 TESTING MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL COVID-19 TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 279. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. GCC COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 285. GCC COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. GCC COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GCC COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS COVID-19 TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS COVID-19 TESTING MARKET SIZE, BY ANTIGEN TESTS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS COVID-19 TESTING MARKET SIZE, BY UPPER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS COVID-19 TESTING MARKET SIZE, BY LOWER RESPIRATORY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS COVID-19 TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS COVID-19 TESTING MARKET SIZE, BY TEST KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS COVID-19 TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS COVID-19 TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS COVID-19 TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 324. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2